$1,689 – $6,489

Effectively Addressing and Remediating FDA's Form 483 Findings, Warning Let...

Event Information

Share this event

Date and Time

Location

Location

The Citrus Club

255 South Orange Avenue

Orlando, FL 32801

View Map

Friends Who Are Going
Event description

Description

This seminar will guide the attendee in effectively handling, addressing and remediating FDA's and other related compliance issues associated such as FDA's Form 483, Warning Letter and Consent Decree Compliance Findings. An effective handling and resolution of Compliance issues will prevent further disciplinary actions such as an FDA's Warning Letter or a formal Consent Decree which ends with a costly impact, fines and possible injunctions by the FDA. Because the impact of non-compliance and remediation of compliance issues are very costly, time consuming and impacting to a business and associated manufactured product including an increasing severity of disciplinary action by the FDA, understanding the triggers, effective preventative and corrective actions and an effective and expedient resolution of such compliance issues will assist a manufacturer of product in preventing expensive remediation of compliance issues, delays to product launch, impact on current commercially available product, overall business reputation, product recall, Fines, loss of impacted Product, loss of business licensure and/or prosecution by the FDA.

Learning Objectives:

Understanding the various implications of not adhering to the rules and regulations of the specific requirements guiding each product types and observed mistakes made by some manufacturers of products that led to the closure of several manufacturing site through an FDA injunction and further bankruptcy of a cGMP product manufacturer will be discussed. This will help in preventing a similar mistake or further detrimental actions from happening or progressing into even more difficult ones. The difficulties and cost associated with remediating an FDA’s Consent decree is very high and most manufacturers of a cGMP drug product have found it very difficult to come out of a consent decree due to the difficulties associated with remediation. Preventing the initiation and progression of compliance related issues and then instituting an appropriate way to address these issues effectively and expeditiously before they become impacting will be discussed. This seminar enhance the attendees’ knowledge as follows:

Seminar Fee Includes:
Lunch
AM-PM Tea/Coffee
Seminar Material
USB with seminar presentation
Hard copy of presentation
Attendance Certificate
$100 Gift Cert for next seminar
  1. A description of what constitutes an FDA’s Form 483 Compliance Findings, Warning Letter or Consent Decree.
  2. The progression and severity of the various FDA compliance findings, triggers of the various progression of the compliance related disciplinary issues and criticality of each type.
  3. Discuss what companies are doing “Right” and “Wrong” when they have compliance related findings and letters such as FDA's form 483 Findings, Warning Letter or Consent Decree.
  4. Discuss the reasons why some companies with recurrent unresolved FDA’s Form 483 findings end up with further progressive compliance issues such as a subsequent FDA’s Warning Letter and/or a Consent decree.
  5. Effective Steps in resolving FDA’s Form 483 Findings, Warning Letter and Consent Decree. The importance of expediting a company’s response to each type of compliance citation from by FDA.
  6. Discuss the entire process of Consent Decree and various scenarios and players in the process through remediation.
  7. Discuss several damaging effects arising from unresolved and difficult compliance related issues such as FDA’s Form 483 Compliance Findings, FDA’s Warning Letter and Consent Decree.
    1. The cost and other impact associated with resolving compliance Remediation Costs.
    2. The overall impact on manufactured products, regulatory filings, employees, product filing, and the overall business and its reputation.
  8. The most effective ways in addressing, handling and resolving or remediating compliance issues associated with FDA 483, Warning Letter and Consent Decree issues.
  9. Discuss several case studies of companies with progressive compliance issues that ended up in Consent Decree.

Areas Covered:

Guidelines: The criticality adhering to the requirements of the Code of Federal Regulations (CFR) and other associated guidelines and best practices cannot be over emphasized. The attendees will be provided a great resource in understanding the various stages of compliance issues and the resulting impact on the manufactured product and business.

Processes and Compliance Issues: A step by step process and description of the various levels of compliance issues and the progressive discipline issued by the FDA such as an FDA's Form 483 Findings through Warning Letters and into a Consent Decree will be addressed. Discussions of what some companies are doing "Right" and "Not Right" in addressing and resolving compliance related issues and triggers of a severe action by the FDA will be discussed in detail.

Cost Effective Ways: Attendees will be able to understand the most effective and cost efficient ways in handling, resolving and/or preventing recurring future difficult compliance related, appropriate remediation process, timelines, overall cost implications associated with unresolved compliance issues.

Case Studies: Several case studies will be discussed on the progression that occurred with some companies that ended up in a Consent Decree situation and how their compliance issues would have been most effectively resolved will be discussed. Learning from past mistakes and preventing further compliance mistakes as observed by these companies with current Consent Decree will be discussed as case studies.

Who will Benefit:

The Seminar will benefit people within the pharmaceutical, biotechnology or medical device industries that currently have a stability testing program but are not savvy about maximizing the use of their data for extending their product’s expiration dating. The employees who will benefit most include:

  • Quality Control Analyst and Management
  • Senior Management
  • Manufacturing Associates and Management
  • Shipping and Distribution Personnel
  • Stability Testing Department Personnel and Management
  • Regulatory Affairs
  • Quality Assurance Analyst and Management
  • Process Design Personnel and Management
  • Drug Packaging Personnel and Management


Day 01(8:00 AM - 5:00 PM)
  • 08.00 AM - 09.00 AM: Registration
  • 09.00 AM: Session Start
  • 9:00 am – 9:30 am
  • Regulations Guiding the Manufacture of cGMP Products and/or Services
    • Understanding the Importance and Criticality of the Code of Federal Regulations (CFR) Guiding the Various Products, Industries and Processes
    • Description of the Various Parts of the CFR
    • Compliance Expectations, Requirements and Specific Roles of Manufacturers of Products Regarding Compliance.
    • Other National and International Regulations Guiding the Manufacture of Various Products and their Relationship and Importance.
  • Session 1
  • 9:30 am – 10:15 am
    • Topic: Types and Levels of FDA’s Regulatory Findings and Disciplinary Actions Relating to Various Compliance Issues
    • Knowledge Base: Attendees will gain an understanding in the following key areas:
      • Summary of what constitutes an FDA’s Form 483 Findings and the sequence of events that triggers its progression into the next stage of FDA’s disciplinary action “FDA’s Warning Letter”.
      • Summary of what constitutes an FDA’s Warning Letter and the sequence of events that triggers its progression into the next stage of FDA’s disciplinary action “Issuance of a Consent Decree”.
      • Understanding what an FDA’s Consent Decree is and what triggers the initiation of a Consent Decree.
      • Detailed Understanding of an FDA’s Form 483 Compliance Issue Findings
      • What triggers an FDA’s Form 483 Compliance Issue Findings?
  • Session 2
  • 10:15 am - 11:00 am
    • What Constitutes an Adequate response time to an FDA’s Form 483 Compliance Issue Findings?
    • What Constitutes an Effective Handling and Response to an FDA’s Form 483 Compliance Issue Findings?
    • How to Resolve an FDA’s Form 483 Compliance Issue Findings?
    • What Some Companies are Doing Well in Effectively Addressing and Resolving an FDA’s Form 483 Compliance Issue Findings?
  • 11:00 am – 11:15 am(Break)
  • Session 3
  • 11:15 am - 12:00 pm
    • What Some Companies Not Doing So Well in Effectively Addressing and Resolving an FDA’s Form 483 Compliance Issue Findings?
    • What Does a Recurring Non-compliance of an FDA Form 483 Compliance Issue Findings mean?
    • Impact and Next Disciplinary Actions if the Compliance Issue Findings are not effectively resolved by Companies.
    • How to Effectively Perform a Remediation of an FDA’s Form 483 Compliance Issue Findings?
    • Remediation Activities Associated with FDA’s Form 483 Compliance Issue Findings?
    • Preparing for Future FDA Visits and Audits after a Previous FDA’s Warning Letter Compliance Issue Findings.
  • 12:00 pm - 1:00 pm (Lunch Break)
  • Session 4
  • 1:00 pm - 2:00 pm
    • Topic: Detailed Understanding of an FDA’s Form 483 Findings-Compliance Issues

      Knowledge Base: Attendees will gain an understanding in the following key areas:

      • What triggers an FDA’s Warning Letter?
      • What Constitutes an Adequate response time to an FDA’s Warning Letter
      • What Constitutes an Effective Handling and Response to an FDA’s Warning Letter
      • How to Resolve an FDA’s Warning Letter
      • What Some Companies are Doing Well in Effectively Addressing and Resolving an FDA’s Warning Letter?
      • What Some Companies Not Doing So Well in Effectively Addressing and Resolving an FDA’s Warning Letter.
  • Session 5
  • 2:00 pm - 3:00 pm
    • What Does a Recurring Non-compliance of an FDA Warning Letter Compliance Issues mean?
    • Impact and Next Disciplinary Actions if FDA’s Warning Letter Compliance Issues are not effectively resolved by Companies.
    • How to Effectively Remediate an FDA’s Warning Letter
    • Remediation Activities Associated an FDA’s Warning Letter Compliance Issue?
    • Preparing for Future FDA Visits and Audits after a Resolution of a Previous FDA’s Warning Letter FDA’s Form 483 Compliance Issue?
  • 3:00 pm - 3:15 pm (Break)
  • 3:15 pm - 4:00 pm(Review of Case Studies)

    Review of Case Studies on Pharmaceutical Stability Testing - FDA’s Warning Letters to Companies: Issues Encountered by Drug Product Manufacturers Based on Failure to Address Compliance Issues, Recurring Form 483 Compliance Issues, Warning Letters and Consent Decree:

    Case Study Category #1 (Companies with Recurring FDA’s Form 483 Compliance Issues):

    • Discussion of several Case Studies relating to companies with a recurring FDA’s Form 483 compliance findings and triggered Warning Letter issuance.
    • What was not done “Right” in addressing the compliance related issues based on the FDA’s Form 483 Findings?
    • Effective ways and approach to resolution that was not applied. Best practices that these companies would have applied that would have prevented the progressive discipline by the FDA into the issuance of an FDA’s Warning Letter.
    • Examples will be discussed and an interactive session on this case study will be applied.

    Case Study Category #2 (Companies with an Issued FDA’s Warning Letter)

    • Discussion of several Case Studies relating to companies with an FDA’s Warning Letter and what triggered the issuance of the FDA’s Warning Letter.
    • What was not done “Right” in addressing the compliance related issues based on the FDA’s Warning Letter?
    • Effective ways and approach to resolution of the Warning Letter that was not applied.
    • Best practices that these companies would have applied that would have prevented the progressive discipline by the FDA into a Consent Decree.
    • Examples will be discussed and an interactive session on this case study will be applied.
  • 4:00 pm - 5:00 pm (Questions and Answer Session)
  • 5:00 pm (Close of Seminar)
Day 02(8:00 AM - 5:00 PM)
  • 8:00 – 9:00 am: Breakfast and Registration
  • 9:00 am – 9:30 am
  • Regulations Guiding the Manufacture of cGMP Products and/or Services
    • Understanding the Importance and Criticality of the Code of Federal Regulations (CFR) Guiding the Various Products, Industries and Processes
    • Description of the Various Parts of the CFR
    • Compliance Expectations, Requirements and Specific Roles of Manufacturers of Products Regarding Compliance.
    • Other National and International Regulations Guiding the Manufacture of Various Products and their Relationship and Importance.
  • Session 1
  • 9:30 am – 10:15 am

    Topic: Effectively Handling, Resolving and Remediating an FDA Issued Consent Decree

    Knowledge Base: The Attendees will gain an understanding in the following key areas:

      • What triggers an FDA’s Consent Decree?
      • Steps that may lead to the issuance of an FDA’s Consent Decree
      • What Constitutes an Effective Handling and Response to an FDA’s Consent Decree?
      • How to Resolve an FDA’s Consent Decree Compliance issues
      • What Some Companies are Doing Well in Effectively Addressing and Resolving an FDA’s Consent Decree Compliance issues.
  • Session 2
  • 10:15 am - 11:00 am
    • What Some Companies Not Doing So Well in Effectively Addressing and Resolving an FDA’s Consent Decree Compliance issues.
    • Impact and Next Disciplinary Actions if FDA’s Consent Decree Compliance issues are not effectively resolved by Companies.
    • How to Effectively Remediate an FDA’s Consent Decree Compliance issues.
      • Remediation Activities Associated an FDA’s Consent Decree Compliance issues.
      • FDA Consent Decree and Third Party Consulting Companies
        • Role of FDA Approved Third Party
        • Role of the Company’s Executives and Employees
        • Outside Consultants and Costs
  • 11:00 am – 11:15 am(Break)
  • Session 3
  • 11:15 am - 12:00 pm
    • Commitments and Timelines Associated with an issued Consent Decree Agreement
      • What is known as Commitments and understanding the Criticality of Consent Decree Commitments
      • Timelines Associated with Consent Decree
      • Fines Associated with Consent Decree Timelines
    • Impact of a Consent Decree on a Business
      • Costs Associated with a Consent Decree
      • Impact to Personnel Within the Company
      • Impact to the Company
      • Impact to all Manufactured and New Products
      • Possible Facility Closure
      • Possible Business Bankruptcy
      • Possible FDA Injunction
      • Possible Debarment-Who may be affected?
      • Product Recall and Investigations
    • Gaining back Reputation after a Consent Decree Compliance Related Issues
    • Preparing for Future FDA Visits and Audits after a Previously Issued Consent Decree.
  • 12:00 pm - 1:00 pm (Lunch Break)
  • Session 4
  • 1:00 pm - 2:00 pm

    Topic: Damaging Effects, Associated Impact and Preventative Measures Associated with FDA’s Form 483, Warning Letter and Consent Decree Compliance Issues

    Knowledge Base: Attendees will gain an understanding in the following key areas:

      • Impact of a Compliance Issues on a Manufactured Product and Business
        • Costs Associated with Compliance Issues
        • Impact on Personnel Within the Company
        • Impact on the Business or Company’s Bottom Line
        • Impact to all New and Existing Manufactured Products
        • Possible Facility Closure
        • Possible Business Bankruptcy
        • Possible FDA Injunction
        • Possible Debarment-Who may be affected?
        • Product Recall and Investigations
  • Session 5
  • 2:00 pm - 3:00 pm

    Case Study Category #3 (Companies with an Issued Consent Decree)

    • Discussion of several Case Studies relating to companies with FDA’s Consent Decree and triggered issuance of the Consent Decree.
    • What was not done “Right” in addressing the compliance issues based on the FDA’s Findings?
    • Effective ways and approach to resolution that were not applied to prevent a Consent Decree.
    • Best practices that these companies would have applied that would have prevented the progressive discipline by the FDA.
    • Examples will be discussed and an interactive session on this case study will be applied.
  • 3:00 pm - 4:00 pm (Open Questions and Answer Session)
  • 4:00 pm - 5:00 pm (Closing Comments and Adjournment)



Charity Ogunsanya

Charity Ogunsanya
CEO and Founder, Pharmabiodevice Consulting LLC

Charity Ogunsanya, is the CEO and founder of Pharmabiodevice Consulting LLC. Ms. Ogunsanya has over 23 years of extensive practical and management experience in various Fortune 100 pharmaceutical, biotechnology, biologics, cell therapy, diagnostics, research and development, radio-pharmaceutical, Contract Manufacturing Organization (CMO) and medical device/IVD companies.

She has been a much sought after SME to assume key roles specifically related to remediation and difficult quality and compliance related deficiencies associated with FDA’s Consent Decree, FDA’s Warning Letters and other regulatory bodies’ inspectional findings. Her remediation work has constantly resulted in several successful national and international regulatory bodies’ inspections, re-inspections and new product approvals.

Her technical expertise covers and goes beyond interpretation, administration and set up of quality assurance, quality/compliance, quality engineering, aseptic processing, contamination control, quality control, microbiology, sterility assurance, stability, vaccine development, new product design, product release testing and medical device sterilization (ethylene oxide (EtO), gamma, radiation, VHP sterilization) systems and operations for compliance to various regulations.

She has a keen working knowledge of the requirements and regulations guiding new and existing products from planning through design, proof of concept, research and development, technology transfer, pre-clinical, clinical, commercial manufacturing, supply chain, regulatory filings, pre-approval inspections, licensure, government affairs, commercialization and post-approval inspections.

She is a member of the Parenteral Drug Association (PDA), American Society of Microbiologists (ASM), and other Scientific Forums and Industry Expert Network. She has a Bachelor of Science degree in Microbiology from the University of Benin-Nigeria and she is currently attaining her Masters in Biotechnology (Biodefense Concentration) at the Johns Hopkins University Advanced Academic Program.



Please contact the event manager Marilyn below for the following:
- Discounts for registering 5 or more participants.
- If you company requires a price quotation.
Event Manager Contact: marilyn.b.turner(at)nyeventslist.com
You can also contact us if you require a visa invitation letter, after ticket purchase.
We can also provide a certificate of completion for this event if required.

NO REFUNDS OR TRANSFER ALLOWED ON REGISTRATIONS
-----------------------------------------------------------------
This Event Listing is Promoted by
New York Media Technologies LLC in association
with METRICSTREAM INC.
http://www.NyEventsList.com
http://www.BostonEventsList.com
http://www.SFBayEventsList.com
-----------------------------------------------------------------
SHU170403CEV



Share with friends

Date and Time

Location

The Citrus Club

255 South Orange Avenue

Orlando, FL 32801

View Map

Save This Event

Event Saved